Research ArticleOriginal Article
Open Access

Association of intron 4 VNTR polymorphism in the NOS3 gene with rapid cycling and treatment resistance in bipolar disorder: a case-control study

Hasan M. Aytac, Mustafa Pehlivan, Yasemin Oyaci and Sacide Pehlivan
Neurosciences Journal October 2022, 27 (4) 229-236; DOI: https://doi.org/10.17712/nsj.2022.4.20220040

References

  1. 1.↵
    1. Machado-Vieira R,
    2. Soares JC.
    [Treatment-resistant mood disorders]. Brazilian Journal of Psychiatry 2007; 29: 48–54. Portuguese
    OpenUrl
  2. 2.↵
    1. Poon SH,
    2. Sim K,
    3. Sum MY,
    4. Kuswanto CN,
    5. Baldessarini RJ.
    Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar Disord 2012; 14: 573–584.
    OpenUrlCrossRef
  3. 3.↵
    1. Muneer A.
    Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers. Psychiatry Investig 2016; 13: 18–33.
    OpenUrl
  4. 4.
    1. Kamal NAM,
    2. Loo JL,
    3. Goon JA,
    4. Damanhuri HA,
    5. Sharip S,
    6. Saini SM, et al.
    Oxidative stress biomarkers in bipolar disorder with suicidal behavior: A systematic review. Journal of Pharmaceutical Negative Results 2019; 10: 6.
    OpenUrl
  5. 5.↵
    1. Aytac HM,
    2. Yazar MS,
    3. Erol A,
    4. Pehlivan S.
    Investigation of inflammation related gene polymorphism of the mannose-binding lectin 2 in schizophrenia and bipolar disorder. Neurosciences (Riyadh) 2021; 26: 346–356.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Nursal AF,
    2. Aytac HM,
    3. Yazar MS,
    4. Oyaci Y,
    5. Pehlivan M,
    6. Pehlivan S.
    TNF-α-308 G/A variant may be associated with bipolar disorder in a Turkish population. Arch Clin Psychiatry 2020; 47: 176–179.
    OpenUrl
  7. 7.
    1. Aytac HM,
    2. Oyaci Y,
    3. Yazar MS,
    4. Erol A,
    5. Pehlivan S.
    Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients diagnosed with schizophrenia or bipolar disorder. J Clin Neurosci 2020; 78: 264–268.
    OpenUrl
  8. 8.↵
    1. Aytac HM,
    2. Pehlivan S,
    3. Pehlivan M,
    4. Oyaci Y.
    Quantitative detection of methylated SOCS-1 in schizophrenia and bipolar disorder considering SOCS-1-1478CA/del polymorphism and clinical parameters. Ir J Med Sci 2022: 1–9.
  9. 9.↵
    1. Oral E,
    2. Halici Z,
    3. Cinar I,
    4. Ozcan E,
    5. Kutlu Z.
    Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels. Clin Psychopharmacol Neurosci 2019; 17: 211–221.
    OpenUrl
  10. 10.↵
    1. Goldstein BI,
    2. Fagiolini A,
    3. Houck P,
    4. Kupfer DJ.
    Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009; 11: 657–662.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Nasyrova RF,
    2. Moskaleva PV,
    3. Vaiman EE,
    4. Shnayder NA,
    5. Blatt NL,
    6. Rizvanov AA.
    Genetic Factors of Nitric Oxide’s System in Psychoneurologic Disorders. Int J Mol Sci 2020; 21: 1604.
    OpenUrl
  12. 12.↵
    1. Förstermann U,
    2. Sessa WC.
    Nitric oxide synthases: regulation and function. Eur Heart J 2012; 33: 829–837.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Tripathi MK,
    2. Kartawy M,
    3. Amal H.
    The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders. Redox Biol 2020: 101567.
  14. 14.↵
    1. Pehlivan S,
    2. Aytac HM,
    3. Ciftci HS,
    4. Oyaci Y,
    5. Pehlivan M,
    6. Nursal AF.
    Investigating the eNOS and IFN-γ Gene Variants Susceptible to Bipolar Disorder or Schizophrenia in a Turkish Cohort. Psychiatry and Clinical Psychopharmacology 2020; 30: 354–361.
    OpenUrl
  15. 15.↵
    1. Antwi-Boasiako C,
    2. Dzudzor B,
    3. Kudzi W,
    4. Doku A,
    5. Dale CA,
    6. Sey F, et al
    . Association between eNOS Gene Polymorphism (T786C and VNTR) and Sickle Cell Disease Patients in Ghana. Diseases 2018; 6; 6: 90.
    OpenUrl
  16. 16.↵
    1. Reif A,
    2. Strobel A,
    3. Jacob CP,
    4. Herterich S,
    5. Freitag CM,
    6. Töpner T, et al.
    A NOS-III haplotype that includes functional polymorphisms is associated with bipolar disorder. Int J Neuropsychopharmacol 2006; 9: 13–20.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Napoli C,
    2. Ignarro LJ.
    Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res 2009; 32: 1103–8.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Bhandary UV,
    2. Tse W,
    3. Yang B,
    4. Knowles MR,
    5. Demaine AG.
    Endothelial nitric oxide synthase polymorphisms are associated with hypertension and cardiovascular disease in renal transplantation. Nephrology (Carlton) 2008; 13: 348–355.
    OpenUrlPubMed
  19. 19.↵
    1. Cassidy F,
    2. Zhao C,
    3. Badger J,
    4. Claffey E,
    5. Dobrin S,
    6. Roche S, et al.
    Genomewide scan of bipolar disorder and investigation of population stratification effects on linkage: Support for susceptibility loci at 4q21, 7q36, 9p21, 12q24, 14q24, and 16p13. Am J Med Genet B Neuropsychiatr Genet 2007; 144: 791–801.
    OpenUrl
  20. 20.↵
    1. Association WM.
    World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. First MB,
    2. Spitzer RL,
    3. Gibbon M,
    4. Williams JB.
    User’s guide for the Structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version: American Psychiatric Pub; 1997.
  22. 22.↵
    1. Çorapçıoğlu A,
    2. Aydemir Ö,
    3. Yıldız M,
    4. Esen A,
    5. Köroğlu E.
    DSM-IV Eksen I Bozuklukları (SCID-I) için yapılandırılmış klinik görüşme, klinik versiyon. Ankara: Hekimler yayın birliği. 1999.
  23. 23.↵
    1. Young RC,
    2. Biggs JT,
    3. Ziegler VE,
    4. Meyer DA.
    A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–435.
    OpenUrlAbstract/FREE Full Text
  24. 24.
    1. Karadağ F,
    2. Oral ET,
    3. Aran Yalçın F,
    4. Erten E.
    Young mani derecelendirme ölçeğinin Türkiye’de geçerlik ve güvenilirliği. Türk Psikiyatri Dergisi 2001; 13: 107–114.
    OpenUrl
  25. 25.
    1. Hamilton M.
    A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
    OpenUrlFREE Full Text
  26. 26.
    1. Akdemir A,
    2. Örsel S,
    3. Dağ İ,
    4. Türkçapar H,
    5. İşcan N,
    6. Özbay H.
    Hamilton Depresyon Derecelendirme Ölçeği (HDDÖ)’nin geçerliği, güvenirliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996; 4: 251–259.
  27. 27.↵
    1. Guy W.
    Clinical global impression. Assessment manual for Psychopharmacology 1976; 4: 217–222.
    OpenUrl
  28. 28.↵
    1. Sachs GS.
    Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215–236.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Association AP.
    Diagnostic and statistical manual of mental disorders (DSM-5®). Fifth Edition. Washington (DC): American Psychiatric Pub; 2013.
  30. 30.↵
    1. Erdem D,
    2. Buyuksimsek M,
    3. Gunaldi M,
    4. Isiksacan N,
    5. Pehlivan S.
    Evaluation of the Relationship between eNOS and Breast Cancer. Tıp Fakültesi Klinikleri Dergisi 2019; 2: 23–27.
    OpenUrl
  31. 31.↵
    1. Lee W-C,
    2. Wang L-Y.
    Simple formulas for gauging the potential impacts of population stratification bias. Am J Epidemiol 2008; 167: 86–89.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.
    1. Pehlivan S,
    2. İnalöz HS,
    3. Nursal AF,
    4. Gülel A,
    5. Pehlivan M.
    Is there any Association between the Functional Variants of the NOS3 Gene and Psoriasis? İstanbul Med J 2018: 19: 152.
    OpenUrl
  33. 33.↵
    1. Erol N,
    2. Kılıç C,
    3. Ulusoy M,
    4. Kececi M.
    Mental health profile in Turkey: a main report. Turkish Republic, Ministry of Health, Ankara. 1998: 77–93.
  34. 34.↵
    1. de Medeiros Alves V
    , e Silva ACP, de Melo Neto VL. Associations between genetic polymorphisms and bipolar disorder. Revista de Psiquiatria Clinica 2011; 39: 34–39.
    OpenUrl
  35. 35.↵
    1. Brown NC,
    2. Andreazza AC,
    3. Young LT.
    An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 2014; 218: 61–68.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Selek S,
    2. Savas HA,
    3. Gergerlioglu HS,
    4. Bulbul F,
    5. Uz E,
    6. Yumru M.
    The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008; 107: 89–94.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Buoli M,
    2. Serati M,
    3. Altamura AC.
    Biological aspects and candidate biomarkers for rapid-cycling in bipolar disorder: A systematic review. Psychiatry Res 2017; 258: 565–575.
    OpenUrl
  38. 38.↵
    1. Kirov G,
    2. Murphy K,
    3. Arranz M,
    4. Jones I,
    5. McCandles F,
    6. Kunugi H, et al.
    Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry 1998; 3: 342–345.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Kirov G,
    2. Norton N,
    3. Jones I,
    4. McCandless F,
    5. Craddock N,
    6. Owen MJ.
    A functional polymorphism in the promoter of monoamine oxidase A gene and bipolar affective disorder. Int J Neuropsychopharmacol 1999; 2: 293–298.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Müller DJ,
    2. de Luca V,
    3. Sicard T,
    4. King N,
    5. Strauss J,
    6. Kennedy JL.
    Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. Br J Psychiatry 2006; 189: 317–323.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Liu L,
    2. Foroud T,
    3. Xuei X,
    4. Berrettini W,
    5. Byerley W,
    6. Coryell W, et al.
    Evidence of association between brain-derived neurotrophic factor (BDNF) gene and bipolar disorder. Psychiatric genetics 2008; 18: 267.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Munkholm K,
    2. Pedersen BK,
    3. Kessing LV,
    4. Vinberg M.
    Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology 2014; 47: 199–211.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Munkholm K,
    2. Poulsen HE,
    3. Kessing LV,
    4. Vinberg M.
    Elevated levels of urinary markers of oxidatively generated DNA and RNA damage in bipolar disorder. Bipolar disorders 2015; 17: 257–268.
    OpenUrl
  44. 44.↵
    1. Kapur V,
    2. Nadella RK,
    3. Raghuraman BS,
    4. Saraf G,
    5. Mishra S,
    6. Srinivasmurthy N, et al.
    Clinical factors associated with lithium treatment response in bipolar disorder patients from India. Asian J Psychiatr 2019; 39: 165–168.
    OpenUrl
  45. 45.↵
    1. Busner J,
    2. Targum SD.
    The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007; 4: 28–37.
    OpenUrl
  46. 46.↵
    1. Rybakowski J,
    2. Suwalska A,
    3. Skibinska M,
    4. Szczepankiewicz A,
    5. Leszczynska-Rodziewicz A,
    6. Permoda A, et al.
    Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005; 38: 166–170.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Porcelli S,
    2. Fabbri C,
    3. Serretti A.
    Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22: 239–258.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Rybakowski J,
    2. Dmitrzak-Weglarz M,
    3. Suwalska A,
    4. Leszczynska-Rodziewicz A,
    5. Hauser J.
    Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder. Pharmacopsychiatry 2009; 42: 20–22.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Mamdani F,
    2. Alda M,
    3. Grof P,
    4. Young LT,
    5. Rouleau G,
    6. Turecki G.
    Lithium response and genetic variation in the CREB family of genes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2008; 147: 500–504.
    OpenUrl
  50. 50.↵
    1. Kim B,
    2. Kim CY,
    3. Lee MJ,
    4. Joo YH.
    Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res 2009; 168: 209–212.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section